WuXi Biologics Recognized as Both Industry and Regional ESG Top-Rated Company by Morningstar SustainalyticsPRNewsWire • 02/21/24
WuXi Biologics Successfully Completes First 1,6000L Manufacturing Run in IrelandPRNewsWire • 01/31/24
WuXi Biologics Launches WuXia ADCC PLUS™ for the Development and Manufacturing of Afucosylated Antibodies that Elicit Enhanced ADCC EffectPRNewsWire • 01/25/24
WuXi Biologics Granted U.S. Patent for Proprietary Bispecific Antibody Technology Platform WuXiBody™PRNewsWire • 01/17/24
WuXi Biologics Successfully Implemented a Fully Integrated Continuous Process with a Breakthrough Productivity of ~6 g/L/day at Pilot ScalePRNewsWire • 11/22/23
Myricx Bio Enters into an Exclusive Antibody License Agreement with WuXi BiologicsGlobeNewsWire • 11/21/23
WuXi Biologics Launches New High-Productivity Bioprocessing Platform WuXiUI™ for Cost-Effective Commercial Manufacturing and Desirable Product QualityPRNewsWire • 10/17/23
IMIDomics Announces Strategic Agreement with WuXi Biologics to Advance IMB1001 Antibody Development for Immune-Mediated Inflammatory DiseasesBusiness Wire • 10/04/23
PharmaEssentia Enters Into Exclusive Global License Agreement With WuXi Biologics for a Myeloid Immune Checkpoint Antibody CandidateBusiness Wire • 10/03/23
WuXi Biologics and Boostimmune Sign MOU for Exclusive Research and Discovery ServicesPRNewsWire • 08/11/23
WuXi Biologics Awarded an ISPE Facility of the Year Award in the Operations CategoryBusiness Wire • 05/24/23